In melanoma models it was demonstrated that stimulation of effector cells with IL-15/IL-15Rα complexes or the IL-15 fusion protein RLI (composed of the N-terminal domain of IL-15Rα coupled via a linker to IL-15) significantly reduced tumor burden [157]. The gene discussed is IL15; the disease is neoplasm.